Indore-based pharmaceutical manufacturer of branded generic formulations for domestic and international markets.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 87 | 101 | 114 | 131 | 144 | 150 | 162 | 165 |
| Borrowings | 0 | 6 | 2 | 5 | 2 | 0 | 0 | 3 |
| Other Liabilities | 33 | 28 | 30 | 25 | 32 | 51 | 54 | 53 |
| Total Liabilities | 140 | 155 | 167 | 182 | 199 | 223 | 238 | 242 |
| AssetsFixed Assets | 7 | 9 | 7 | 11 | 11 | 21 | 21 | 20 |
| CWIP | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 51 | 75 | 78 | 98 | 116 | 118 | 145 | 142 |
| Other Assets | 81 | 71 | 82 | 73 | 72 | 84 | 71 | 80 |
| Total Assets | 140 | 155 | 167 | 182 | 199 | 223 | 238 | 242 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | -1 | 18 | -2 | 10 | 9 | 4 | 18 | 10 |
| Cash from Investing | -15 | -11 | 6 | -16 | 2 | -13 | -12 | -12 |
| Cash from Financing | -5 | -1 | 0 | 5 | -4 | 3 | -5 | 2 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -2 | 15 | -5 | 8 | 8 | -3 | 7 | 6 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
ALPA · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.